GALDERMA
8.2.2024 07:01:31 CET | Business Wire | Press release
Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersion will put the sensitive skin science behind its formulas to the ‘ultimate skin stress test’ at New York Fashion Week (NYFW).
As an extension of the brand’s ‘We Do Skin, You Do You’ campaign, Cetaphil’s NYFW activation will enlist influencers and consumers from 14 different countries to be the ‘Face of Cetaphil.’ They will have entered a global contest to win a trip to New York City, where they will act as on-the-ground correspondents alongside other influencers. The delegates will participate in 48 hours of Fashion Week events and activations putting Cetaphil’s sensitive skincare formulas to the test.
“In 2022, we debuted the global ‘We Do Skin. You Do You’ campaign to help empower those with sensitive skin to do more of the things they love – without hesitation. This year, with the ‘Face of Cetaphil,’ we are bringing the campaign to life by tapping into a cultural moment that is very relevant to our consumers. New York Fashion Week is the perfect place to put the brand at the forefront of where fashion, beauty and skincare intersect.”
GERRY MUHLE
|
|
The initiative includes partnerships with contemporary fashion brand Alice + Olivia, modeling and talent agency Wilhelmina International Inc. and global fashion and media brand, Highsnobiety. The competition winners will be joined by sensitive skin expert Dr. Lindsey Zubritsky, board-certified dermatologist at Premier Dermatology and Skin Cancer Center in Ocean Springs, Mississippi, U.S.
“Some cosmetics are a main trigger of sensitive skin, due to the inclusion of potentially irritating ingredients and regular usage. Similarly for clothing, when fabrics interact with skin that has an interrupted skin barrier, products can lead to irritated skin or skin conditions such as contact dermatitis. Scientific research is foundational to everything Cetaphil does, and research has shown that sensitive skin needs extra care. Cetaphil products can help restore and rebuild the skin moisture barrier, helping to reduce skin aggravation. This ultimately helps people feel comfortable in their own skin – and in their beauty and fashion looks.”
DR. LINDSEY ZUBRITSKY
|
|
As Alice + Olivia’s exclusive skincare sponsor, Cetaphil will have a strong presence backstage at one of Fashion Week’s hottest shows. The partnership will include a ‘skincare prep’ area where models will have the opportunity to meet with a Cetaphil skin expert and have their skin prepped using Cetaphil products. These include the Gentle Skin Cleanser, Healthy Renew Face Serum and Moisturizing Lotion, which ensure a hydrated canvas for makeup and clothing application.
“Over many NYFW seasons, I’ve learned how important a great skincare routine is to make up for the long hours and lack of sleep that go into making our beautiful shows a reality. We’re so excited to partner with Cetaphil this season as our skincare sponsor. Glowing skin is the ultimate accessory, and their products work magic to protect and hydrate.”
STACEY BENDET
|
|
Through Cetaphil’s partnership with Wilhelmina Modeling Agency, attendees will also get exclusive access to a group of models who are walking in NYFW shows. These experiential, behind-the-scenes moments will give them an insider’s look at Fashion Week, seeing how it impacts skin, through the eyes of a model.
A Cetaphil x Highsnobiety pop-up will take place on Saturday, February 10 from 11:00 AM to 6:00 PM. The space will serve as a fashion-forward sensitive skin sanctuary where New Yorkers can relax and refuel amidst the hustle and bustle of Fashion Week. The pop-up will be completed with skin consultations, beauty services, custom hydrating beverages and more.
To follow the Face of Cetaphil throughout NYFW, check out your country’s Cetaphil handles on Instagram and TikTok. The brand will be sharing content across its channels.
About Cetaphil
Seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula to clean without stripping and moisturize without clogging. Today, Cetaphil is dermatologist-recommended for sensitive skin and recognized around the world. With the help of leading skincare experts, Cetaphil continues to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin’s health every day. For more information, visit www.cetaphil.com.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207631228/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom